Policy makers need to be more realistic about the prospects for future growth, particularly when it comes to China's demographic challenges.
Justin Yifu Lin, an economics professor at Peking University and former World Bank Chief Economist, speaks during a session on emerging economies at the World Economic Forum Annual Meeting, January 25, 2018. Credit: World Economic Forum via Flickr
Earlier this month, the ratings agency Moody’s cut its outlook on China’s sovereign credit rating to negative, citing risks from a deepening property crisis and a prolonged growth slowdown. In fact, Moody’s now predicts that annual economic growth will fall to 4 percent in 2024 and 2025, before slowing further, to 3.8 percent, on average, for the rest of the decade. Potential growth will decline to 3.5 percent by 2030. A major driver of this slowdown will be “weaker demographic
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from Andrew Peaple.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
At the height of the pandemic, Chinese vaccine maker Sinovac was a hero and one of the country’s most promising companies. But its success masked a protracted dispute between rival investors and management for control of the cash-rich company. The Wire China investigates what went wrong.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OKPrivacy policy
